Asterisk Mag “How Long Til We’re All on Ozempic? Over 100 million Americans, and possibly many more, could benefit from GLP-1 drugs. When can they expect to get them?”

Posted by AMagicalKittyCat

4 Comments

  1. AMagicalKittyCat on

    >My forecast predicts that the supply of GLP-1s will increase from eight million patient-years to roughly enough for approximately 23 million Americans by 2030. Still, this is only enough supply for about 15% of the 147 million Americans with diabetes or obesity.

    >Most patients who want them will not have access to these drugs in the near future. The need is vast, especially abroad, where rollouts are being delayed until demand in the United States can be met. And as indications continue to be added for conditions ranging from heart disease to potentially even alcoholism, demand will only grow. It will likely be many years before these drugs become widely available to the patients who need them. It takes a long time to make a miracle.

    I think we desperately need some insane supply focused policy if ozempic and other semiglutides continue to show such promise without major downsides. A fix to not just one but several of society’s greatest ills might genuinely be here. We shouldn’t get our hopes up too much, but the evidence keeps growing stronger and even in the worst case scenarios they would need *serious* downsides to not be worth it.

  2. Jefe_Chichimeca on

    Easy access to Ozempic appears to be more effective than government anti-obesity campaigns, potentially reducing healthcare costs significantly and enhancing productivity as well as life expectancy. I guess that in two years after it becomes a generic in China there will be a lot of contraband.

Leave A Reply